Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (275)	8/24/2000 9:38:26 AM
From: nigel bates	Respond to of 438

Flatlined may be taking it a little too far .... Aug. 24 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO - news) today announced it has licensed to Myriad Genetics, Inc. (Nasdaq: MYGN - news) non-exclusive access to its cancer diagnostic patent rights related to an undisclosed gene implicated in hereditary colon cancer. In September 2000, Myriad plans to launch a predictive medicine test for hereditary colon cancer called COLARIS(TM) that detects mutations in this gene and an additional gene that is not part of the license agreement. Mutations in either gene, in conjunction with a family history of colon cancer, indicate increased risk for developing the disease. Additionally, the same mutations also substantially increase a woman's risk of endometrial cancer. Under the license agreement, Genzyme Molecular Oncology received from Myriad an up-front payment and will receive royalties on each COLARIS test performed. Further financial details were not disclosed. ``This agreement is evidence of the continued value of Genzyme Molecular Oncology's intellectual property in expanding our diagnostic licensee base, which already includes Affymetrix, LabCorp, and EXACT Laboratories,'' said Gail Maderis, president, Genzyme Molecular Oncology. ``As additional data from the Human Genome Project is analyzed and as more molecular therapeutics reach clinical and commercial development, we expect the interest in cancer diagnostics to continue to grow.'' Myriad has stated that its COLARIS test will provide the same high standard quality to researchers and clinicians for colon and endometrial cancer that has previously been achieved in breast and ovarian cancer with Myriad's BRACAnalysis® test. Myriad has announced that it will begin accepting samples for testing with COLARIS nationwide next month. Genzyme Molecular Oncology has an extensive portfolio of intellectual property related to cancer gene diagnostics based on the work of its collaborators, Drs. Kenneth Kinzler and Bert Vogelstein at The Johns Hopkins University. Genzyme Molecular Oncology is out-licensing its diagnostic rights to generate funds to help support its internal cancer therapeutic development efforts.

To: Mike McFarland who wrote (275)	8/24/2000 10:39:47 AM
From: Spekulatius	Read Replies (2) \| Respond to of 438

I did buy my initial position in GZMO at a bit more than 11$ and then added at about 8$. When it spiked up to 15$+, i flipped the shares in my IRA but bought them back when it was below 12$. Since its a microcap, I would never establish a huge position (as you did)and I also like to take trading profits but I like to hold a reasonable position. The angiogenesis news has made GZMO more valuable, IMHO and should have raised some eyebrows in the industry. I am hoping for a real big deal with a pharma or even better with a genomics company (Millenium, Incyte).